Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. demonstrates a robust financial trajectory, highlighted by a year-over-year increase in operating expenses of only $2.0 million, indicating a controlled growth in costs amidst rising business activity. The company is poised for sustained double-digit revenue growth, supported by a strategic focus on increasing utilization rates among its growing light adjustable lens (LDD) installed base and enhancing volumes through targeted engagement initiatives. Furthermore, management has raised gross margin guidance to 76-77% for 2025, reflecting optimism about operational efficiency and profitability, alongside a careful management of operating expenses anticipated in the range of $145-155 million.

Bears say

RxSight Inc. has experienced a notable decline in monthly utilization of its light adjustable lenses (LALs), falling to 8.0 LALs per laser delivery device (LDD) in 3Q25 from 8.7 in 2Q25 and 10.1 in 3Q24, indicating a negative trend in operational efficiency. The company's revenue also dropped by 14% year-over-year to $30.3 million, coinciding with a significant decrease in LDD placements, which plummeted by 68% year-over-year and 38% quarter-over-quarter to only 25 units in 2Q25, trailing behind consensus expectations. Additionally, key risks remain, including limited adoption of their technology due to the necessity for an incremental capital investment, challenges in commercial execution, growing competition in the intraocular lens market, and concerns over the potential need for dilutive financing.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.